这篇综述系统阐述了新生儿Fc受体（FcRn）在IgG抗体稳态调控中的核心作用，及其作为创新治疗靶点在自身免疫性疾病中的应用价值。文章详细解析了FcRn与IgG的pH依赖性结合机制（1:2化学计量比），综述了efgartigimod（ARGX-113）、rozanolixizumab（UCB7665）等5种临床阶段 ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

In the vast landscape of antibody drug development, the interaction between IgG and neonatal Fc receptor ( FcRn ) stands as an undeniable cornerstone. This interaction profoundly shapes the ...

SPRING HOUSE, PA — Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker ... The drug’s binding is pH-independent, a trait that makes it ...

This year at AAN, we are sharing more evidence demonstrating the long-term benefits of VYVGART for patients living with gMG and CIDP,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx.

By blocking FcRn, nipocalimab aims to lower circulating IgG levels without impacting overall immune function. The drug's pH-independent binding is particularly noteworthy, as it may allow for the ...

Largest safety data set on FcRn blocking demonstrates consistent ... patients living with gMG and CIDP,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx. “Our breadth of data ...